Sunmax Biotechnology Co., Ltd. (TPEX: 4728)
Taiwan
· Delayed Price · Currency is TWD 276.00
-0.50 (-0.18%)
Dec 19, 2024, 12:36 PM CST
Sunmax Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,743 | 1,689 | 1,400 | 1,036 | 855.85 | 594.15 | Upgrade
|
| Revenue Growth (YoY) | 4.13% | 20.64% | 35.19% | 21.01% | 44.05% | 95.40% | Upgrade
|
| Cost of Revenue | 314.37 | 284.1 | 207.27 | 141.21 | 154.65 | 79.97 | Upgrade
|
| Gross Profit | 1,429 | 1,405 | 1,193 | 894.45 | 701.2 | 514.18 | Upgrade
|
| Selling, General & Admin | 482.71 | 481.35 | 407.22 | 502.21 | 353.73 | 314.05 | Upgrade
|
| Research & Development | 32.76 | 28.74 | 17.97 | 24.63 | 17.53 | 22.61 | Upgrade
|
| Operating Expenses | 515.46 | 510.1 | 424.8 | 527.08 | 368.89 | 339.12 | Upgrade
|
| Operating Income | 913.53 | 894.8 | 768 | 367.37 | 332.31 | 175.06 | Upgrade
|
| Interest Expense | -6.09 | -2.94 | -1.35 | -2.81 | -2.92 | -2.74 | Upgrade
|
| Interest & Investment Income | 16.85 | 13.2 | 7.18 | 3.79 | 8.45 | 10.95 | Upgrade
|
| Currency Exchange Gain (Loss) | 16.12 | 1.95 | 2.43 | -3.03 | 3.98 | -8.66 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.07 | 2.51 | 0.46 | -6.23 | 4.08 | -22.09 | Upgrade
|
| EBT Excluding Unusual Items | 945.48 | 909.52 | 776.71 | 359.1 | 345.91 | 152.51 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -8.32 | 1.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.14 | -0.13 | 0.46 | -2.1 | 0.17 | - | Upgrade
|
| Other Unusual Items | - | - | 0.01 | 0.49 | - | - | Upgrade
|
| Pretax Income | 945.34 | 909.39 | 777.18 | 357.49 | 337.76 | 154.42 | Upgrade
|
| Income Tax Expense | 246.39 | 283.68 | 243.35 | 111.84 | 99.68 | 53.97 | Upgrade
|
| Earnings From Continuing Operations | 698.95 | 625.71 | 533.83 | 245.64 | 238.08 | 100.45 | Upgrade
|
| Net Income | 698.95 | 625.71 | 533.83 | 245.64 | 238.08 | 100.45 | Upgrade
|
| Net Income to Common | 698.95 | 625.71 | 533.83 | 245.64 | 238.08 | 100.45 | Upgrade
|
| Net Income Growth | 20.16% | 17.21% | 117.32% | 3.18% | 137.02% | 34.54% | Upgrade
|
| Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 55 | 55 | Upgrade
|
| Shares Change (YoY) | -0.06% | -0.01% | 0.03% | -0.02% | -0.00% | 0.45% | Upgrade
|
| EPS (Basic) | 12.83 | 11.49 | 9.80 | 4.51 | 4.37 | 1.84 | Upgrade
|
| EPS (Diluted) | 12.82 | 11.47 | 9.79 | 4.51 | 4.37 | 1.84 | Upgrade
|
| EPS Growth | 20.27% | 17.16% | 117.07% | 3.20% | 137.50% | 33.69% | Upgrade
|
| Free Cash Flow | 476.37 | 740.9 | 489.99 | -9.74 | 257.11 | 275.82 | Upgrade
|
| Free Cash Flow Per Share | 8.74 | 13.59 | 8.98 | -0.18 | 4.71 | 5.06 | Upgrade
|
| Dividend Per Share | 11.000 | 11.000 | 9.500 | 4.400 | 2.000 | 1.500 | Upgrade
|
| Dividend Growth | 15.79% | 15.79% | 115.91% | 120.00% | 33.33% | 25.00% | Upgrade
|
| Gross Margin | 81.97% | 83.18% | 85.20% | 86.36% | 81.93% | 86.54% | Upgrade
|
| Operating Margin | 52.40% | 52.98% | 54.85% | 35.47% | 38.83% | 29.46% | Upgrade
|
| Profit Margin | 40.09% | 37.05% | 38.13% | 23.72% | 27.82% | 16.91% | Upgrade
|
| Free Cash Flow Margin | 27.32% | 43.87% | 35.00% | -0.94% | 30.04% | 46.42% | Upgrade
|
| EBITDA | 976.96 | 936.47 | 800.67 | 397.3 | 345.86 | 182.85 | Upgrade
|
| EBITDA Margin | 56.04% | 55.45% | 57.19% | 38.36% | 40.41% | 30.78% | Upgrade
|
| D&A For EBITDA | 63.43 | 41.67 | 32.68 | 29.94 | 13.55 | 7.79 | Upgrade
|
| EBIT | 913.53 | 894.8 | 768 | 367.37 | 332.31 | 175.06 | Upgrade
|
| EBIT Margin | 52.40% | 52.98% | 54.85% | 35.47% | 38.83% | 29.46% | Upgrade
|
| Effective Tax Rate | 26.06% | 31.19% | 31.31% | 31.29% | 29.51% | 34.95% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.